A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis

ClinicalTrials.gov ID: NCT04308681

Public ClinicalTrials.gov record NCT04308681. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 20, 2026, 6:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants With Pulmonary Fibrosis

Study identification

NCT ID: NCT04308681
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Bristol-Myers Squibb; Industry
Enrollment: 403 participants

Conditions and interventions

Conditions

Pulmonary Fibrosis

Interventions

BMS-986278 Drug
BMS-986278 Placebo Other

Drug · Other

Eligibility (public fields only)

Age range: 21 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 28, 2020
Primary completion: Aug 3, 2022
Completion: Sep 21, 2023
Last update posted: Feb 2, 2026

2020 – 2023

United States locations

U.S. sites: 21
U.S. states: 15
U.S. cities: 21

Facility	City	State	ZIP	Site status
Local Institution - 0032	Birmingham	Alabama	35294	—
Local Institution	Phoenix	Arizona	85006	—
Local Institution - 0028	Los Angeles	California	90024	—
Local Institution - 0043	Stanford	California	94305-528	—
University of Colorado Anschutz Medical Campus-Department of Medicine	Aurora	Colorado	80045	—
Local Institution - 0006	Denver	Colorado	80206	—
Local Institution - 0171	New Haven	Connecticut	06520	—
Local Institution - 0035	Gainesville	Florida	32610	—
Local Institution - 0166	Orlando	Florida	32803	—
Local Institution - 0078	Atlanta	Georgia	30309	—
Local Institution - 0031	Kansas City	Kansas	66160	—
Local Institution - 0154	Baltimore	Maryland	21224	—
Local Institution - 0003	Boston	Massachusetts	02135	—
Local Institution - 0030	Chesterfield	Missouri	63017	—
Local Institution - 0036	St Louis	Missouri	63110	—
Local Institution - 0029	Cincinnati	Ohio	45267	—
Local Institution - 0164	Columbus	Ohio	43221	—
Local Institution	Hershey	Pennsylvania	17033	—
Local Institution	Nashville	Tennessee	37232	—
Local Institution - 0096	Charlottesville	Virginia	22908	—
Local Institution	Falls Church	Virginia	22042	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 98 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04308681, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 2, 2026 · Synced May 20, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04308681 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →